

Image:

Table 1. Comparison of socio-demographic factors according to depression and suicidal ideation^a

Variable ^a		Total ^a	Depression ^a	P ^a	Suicidal ideation ^a	P ^a
Gender ^a	Man ^a	586(24.2) ^a	133(22.7) ^a	0.058 ^a	93(15.9) ^a	<0.001 ^a
	Woman ^a	1837(75.8) ^a	489(26.6) ^a		425(23.1) ^a	
Age ^a	65–69 ^a	196(8.1) ^a	29(14.8) ^a	0.001 ^a	36(18.4) ^a	0.014 ^a
	70–74 ^a	408(16.8) ^a	94(23) ^a		76(18.6) ^a	
	75–79 ^a	561(23.2) ^a	156(27.8) ^a		116(20.7) ^a	
	80–84 ^a	697(28.8) ^a	176(25.3) ^a		141(20.2) ^a	
	≥85 ^a	561(23.2) ^a	167(29.8) ^a		149(26.6) ^a	
Living status ^a	Alone ^a	1354(55.9) ^a	424(31.3) ^a	<0.001 ^a	323(23.9) ^a	0.001 ^a
	With others ^a	1069(44.1) ^a	198(18.5) ^a		195(18.2) ^a	
Perceived health status ^a	Poor ^a	1352(55.8) ^a	483(35.7) ^a	<0.001 ^a	374(27.7) ^a	<0.001 ^a
	Neutral ^a	602(24.8) ^a	92(15.3) ^a		89(14.8) ^a	
	Healthy ^a	469(19.4) ^a	47(10) ^a		55(11.7) ^a	
Physical disease ^a	Yes ^a	2126(87.7) ^a	579(27.2) ^a	<0.001 ^a	482(22.7) ^a	<0.001 ^a
	No ^a	297(12.3) ^a	43(14.5) ^a		36(12.1) ^a	
Physical Function ^a	restricted ^a	45(1.9) ^a	15(3.3) ^a	0.235 ^a	18(40) ^a	0.002 ^a
	possible ^a	2378(98.1) ^a	607(25.5) ^a		500(21) ^a	
Physical Function ^a	unable ^a	34(1.4) ^a	15(44.1) ^a	0.013 ^a	13(38.2) ^a	0.016 ^a
	possible ^a	2389(98.6) ^a	607(25.4) ^a		505(21.1) ^a	
Physical Function ^a	unable ^a	96(4) ^a	39(40.6) ^a	0.001 ^a	39(40.6) ^a	<0.001 ^a
	possible ^a	2327(96) ^a	583(25.1) ^a		479(20.6) ^a	

Values are presented as a number (%). ^aGDS-15 = 8. ^aIncludes single/separated/divorced/widowed.

Image 2:

Table 2. Comparison of COVID-19 related factors according to depression and suicidal ideation^a

Variable ^a		Total ^a	Depression ^a		Suicidal ideation ^a	
		N(%)	N(%)	P ^a	N(%)	P ^a
Worry of COVID-19 infection ^a	Yes ^a	1490(61.5) ^a	464(31.1) ^a	<0.001 ^a	355(23.8) ^a	<0.001 ^a
	No ^a	933(38.5) ^a	158(16.9) ^a		163(17.5) ^a	
Worry of COVID-19 infection of family ^a	Yes ^a	1779(73.4) ^a	522(29.3) ^a	<0.001 ^a	407(22.9) ^a	0.003 ^a
	No ^a	644(26.6) ^a	100(15.5) ^a		111(17.2) ^a	
Worry of damage to others ^a	Yes ^a	1773(73.2) ^a	518(29.2) ^a	<0.001 ^a	408(23) ^a	0.001 ^a
	No ^a	650(26.8) ^a	104(16) ^a		110(16.9) ^a	
Loss of income ^a	Yes ^a	813(33.6) ^a	271(33.3) ^a	<0.001 ^a	204(25.1) ^a	0.002 ^a
	No ^a	1610(66.4) ^a	351(21.8) ^a		314(19.5) ^a	
Restriction of daily activity ^a	Yes ^a	1227(50.6) ^a	400(32.6) ^a	<0.001 ^a	296(24.1) ^a	0.001 ^a
	No ^a	1196(49.4) ^a	222(18.6) ^a		222(18.6) ^a	

Image 3:

Table 3. Factors associated with depression and suicidal ideation according to multivariate logistic regression^a

Variable ^a	Depression ^a			Suicidal ideation ^a		
	OR ^a	95% CI ^a	P ^a	OR ^a	95% CI ^a	P ^a
Gender_Male ^a	0.822 ^a	0.634–1.066 ^a	0.139 ^a	1.342 ^a	1.007–1.787 ^a	0.045 ^a
Living status_Alone ^a	1.691 ^a	1.355–2.109 ^a	<0.001 ^a	0.933 ^a	0.737–1.18 ^a	0.563 ^a
Perceived health status_Poor(reference Healthy) ^a	3.977 ^a	2.823–5.603 ^a	<0.001 ^a	1.665 ^a	1.186–2.337 ^a	0.003 ^a
Physical Function_House work_unable ^a	1.610 ^a	0.96–2.698 ^a	0.071 ^a	1.868 ^a	1.098–3.177 ^a	0.021 ^a
Worry of COVID-19 infection_Yes ^a	1.418 ^a	1.094–1.942 ^a	0.010 ^a	1.088 ^a	0.798–1.483 ^a	0.593 ^a
Loss of income_Yes ^a	1.258 ^a	0.994–1.593 ^a	0.056 ^a	1.205 ^a	0.929–1.563 ^a	0.160 ^a
Restriction of daily activity_Yes ^a	1.509 ^a	1.193–1.909 ^a	0.001 ^a	0.962 ^a	0.745–1.243 ^a	0.769 ^a
Depression high risk_Yes ^a	— ^a	— ^a	— ^a	4.505 ^a	3.598–5.642 ^a	<0.001 ^a

Conclusions: These findings showed that increased risk factor for depression and suicidal ideation in community dwelling elderly during COVID-19 pandemic. We confirmed that feelings of isolation and negative perception of health were risk factors on depression in community dwelling elderly in the context of the COVID – 19 pandemic. Also male, poor self-perceived health status, difficulty of independent living and worry and depression are increased the risk of suicidal ideation among the elderly.

Disclosure of Interest: None Declared

Schizophrenia and Psychosis 1

O0127

Antipsychotic treatment and cognitive function in patients with schizophrenia

M. A. Tumova^{1*}, A. A. Stepanova², M. G. Yanushko¹, A. P. Kotsyubinsky² and M. V. Ivanov¹

¹Biological therapy of the mentally ill and ²Department of Biopsychosocial Rehabilitation, V.M. Bekhterev National medical research center psychiatry and neurology, Saint Petersburg, Russian Federation

*Corresponding author.

doi: 10.1192/j.eurpsy.2023.328

Introduction: It is known that cognitive impairment is one of the main symptoms of schizophrenia, which determines the functional outcome. The question of the effect of antipsychotics on the cognitive functions of these patients is still unresolved. Cognitive impairment while taking antipsychotics is thought to be mostly related to extrapyramidal abnormalities. In practice, it is difficult to distinguish what causes a patient's complaints of cognitive decline. Is it related to taking the medication? Or a worsening mental state? Age, lifestyle, etc.?

Objectives: We analyzed the relationship of cognitive impairment with the severity of extrapyramidal symptoms, mental status gravity, age, and dose of antipsychotic and cholinergic medication at weeks 2 and 8 of treatment.

Methods: We examined 37 patients with schizophrenia on stable antipsychotic treatment at weeks 2 and 8 of therapy. Thirty patients received a 2nd-generation antipsychotic, and seven patients received a 1st-generation antipsychotic. The anticholinergic drug was trihexyphenidyl. The antipsychotic dose was estimated in olanzapine equivalent. Extrapyramidal symptoms were assessed by The Scale for Extrapyramidal Symptoms (SAS), severity of mental condition was rated by The Positive and Negative Syndrome Scale (PANSS), cognitive function was measured by The Brief Assessment of Cognition in Schizophrenia (BACS).

Results: As previously described, patients with more severe extrapyramidal symptoms tended to have lower BACS composite scores (rxy = -0.318, p-value = 0.055) at week 8 of therapy. The total score on the SAS scale, as expected, only negatively correlated with scores on the Token Motor Task test (rxy = -0.412, p-value = 0.011) at the 8th week of therapy. There were also negative correlations between

Token Motor Task scores and trihexyphenidyl dose ($r_{xy} = -0.496$, $p\text{-value} = 0.002$). At both weeks 2 and 8, there was a negative relationship between age and Symbol Coding scores ($r_{xy} = -0.387$, $p\text{-value} = 0.018$; $r_{xy} = -0.35$, $p\text{-value} = 0.034$, respectively). Verbal Fluency scores were lower in patients with high scores on the PANSS excitement component and at week 2 ($r_{xy} = -0.42$, $p\text{-value} = 0.01$), this trend continued at week 8 ($r_{xy} = -0.31$, $p\text{-value} = 0.063$). Tower of London scores were negatively associated at week 8 with cognitive and positive PANSS scores ($r_{xy} = -0.46$, $p\text{-value} = 0.004$; $r_{xy} = -0.336$, $p\text{-value} = 0.042$, respectively). **Conclusions:** Thus, we have demonstrated that cognitive impairment in patients with schizophrenia is associated with various factors, and not only antipsychotic treatment.

Disclosure of Interest: None Declared

O0128

Changes in inflammatory parameters and their impact on clinical symptoms in patients suffering from schizophrenia

B. Nycz and K. Krysta*

Department of Rehabilitation Psychiatry, Medical University of Silesia, Katowice, Poland

*Corresponding author.

doi: 10.1192/j.eurpsy.2023.329

Introduction: One of the factors influencing the symptoms of schizophrenia, which may indicate changes in the cognitive functioning of patients, is the fluctuating level of inflammatory cytokines.

Objectives: The aim of the review was to analyze the available literature on the importance of selected inflammatory factors [interleukin-1 β (IL-1 β), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), of tumor necrosis α (TNF- α)] in schizophrenia and the assessment of the impact of changes in cytokine levels on the occurrence of schizophrenia symptoms.

Methods: For this purpose, available scientific publications from following databases: PubMed, Scopus, Google Scholar were used to prove that the levels of selected inflammatory parameters changed in people suffering from schizophrenia. Moreover, fluctuations in cytokine concentrations influenced the occurrence of negative symptoms of schizophrenia, including cognitive disorders, as well as psychotic symptoms.

Results: An increase in the concentration of IL-1 β in the cerebrospinal fluid of patients with the first episode of schizophrenia has been described, which may indicate the involvement of the cytokine in the inflammatory process involving the CNS. The increased level of IL-6 is associated with the occurrence of psychotic disorders, it is also noted in stressful conditions. IL-6 is qualified as an indicator of exacerbation of schizophrenia, which normalizes after antipsychotic treatment. In the blood of patients with paranoid schizophrenia, elevated levels of IL-8 and IL-6 were detected compared to healthy individuals, which indicates the development of an inflammatory process in schizophrenia. The relationship between the level

of IL-8 in women in the second trimester of pregnancy and the risk of developing schizophrenia spectrum disorder in children has been proven. Untreated patients with acute psychotic symptoms showed an increase in the level of TNF- α in the blood serum (compared to healthy subjects). An increase in the level of TNF- α in the blood serum of patients with an acute relapse of schizophrenia or the first episode of psychosis was also demonstrated. In conclusion, the relationship of IL-6 and TNF- α with the occurrence of psychotic disorders, the relationship of IL-1 β with the appearance of changes in mood, behavior, including cognitive dysfunction, the relationship of IL-8 with the risk of developing schizophrenia spectrum disorder in children, the relationship of reduced concentrations of IL-10 with the intensification of negative symptoms, including cognitive deficits.

Conclusions: In conclusion, the analysis showed that patients with schizophrenia fluctuate in the concentration of inflammatory cytokines, which affects the occurrence of clinical symptoms.

Disclosure of Interest: None Declared

O0129

Changes in quality of life in treatment-resistant schizophrenia patients undergoing VR-assisted therapy for auditory verbal hallucinations: A content analysis

M. Beaudoin^{1,2,3*}, S. Potvin^{1,2}, K. Phraxayavong² and A. Dumais^{1,2,4}

¹Psychiatry and addictology, University of Montreal; ²Research Center, Institut universitaire en sante mentale de Montreal; ³Faculty of Medicine, McGill University and ⁴Research Center, Institut national de psychiatrie légale Philippe-Pinel, Montreal, Canada

*Corresponding author.

doi: 10.1192/j.eurpsy.2023.330

Introduction: VR-Assisted Therapy (VRT) for auditory verbal hallucinations has been demonstrated to have a significant impact on the symptoms, beliefs, and quality of life of patients with treatment-resistant schizophrenia. However, little is known about how these changes are implemented into their lives and on which aspects these improvements occur.

Objectives: This study aimed to qualitatively explore changes in the quality of life of patients who underwent VRT in the context of an ongoing clinical trial.

Methods: Ten consecutive patients enrolled in an ongoing clinical trial were assessed using semi-guided interviews before as well as 3 months after VRT. These encounters have been recorded and transcribed. Then, the content of the participants' discourse was thoroughly analyzed, leading to the generation of an extensive theme grid. Each utterance was then coded by at least two members of the research team, and each disagreement was then discussed in a group format until a consensus was reached. As the cases were analyzed, the grid was adapted in a back and forth manner. New participants were included until data saturation occurred.

Results: The content analysis allowed the identification of nine main themes representing different aspects of the patients' quality